ALEBUND-B (09637) climbed more than 6% in early trading, last up 3.82% at HK$33.7, with turnover reaching HK$12.45 million.

On the news front, Hang Seng Indexes Company recently announced the results of its quarterly index review as of June 30, 2026, with ALEBUND-B being added to the Hang Seng Composite Index. The index changes will be implemented after market close on Friday, September 4, and take effect on Monday, September 7, at which point the Shanghai and Shenzhen stock exchanges will correspondingly adjust the eligible scope of stocks for the Stock Connect southbound trading channel. Should the inclusion go through smoothly, ALEBUND-B will enter the investable universe for southbound capital, potentially improving both liquidity and valuation anchoring simultaneously.

Notably, the company is slated to release its first interim results since listing on August 26, and the combination of index inclusion expectations and the earnings window could form a dual catalyst for the stock.

A research report from Huatai Securities indicates that ALEBUND-B previously entered into an exclusive commercialization partnership with Roche for Mircera, which is currently the company's only product to have reached commercial launch. The brokerage forecasts that Mircera could achieve a sales peak of approximately RMB 1 billion in China by 2034, underpinned by the anticipated continued rise in the penetration rate of long-acting formulations in the country, the company's established and mature commercialization team providing strong support for product promotion, and the resolution of Roche's supply bottleneck issues.